The chemokine CCL28 is constitutively expressed by epithelial cells at several mucosal sites and is thought to function as a homeostatic chemoattractant of subpopulations of T cells and IgA B cells and to mediate antimicrobial activity. We report herein on the regulation of CCL28 in human colon epithelium by the proinflammatory cytokine IL-1, bacterial flagellin, and n-butyrate, a product of microbial metabolism. In vivo, CCL28 was markedly increased in the epithelium of pathologically inflamed compared with normal human colon. Human colon and small intestinal xenografts were used to model human intestinal epithelium in vivo. Xenografts constitutively expressed little, if any, CCL28 mRNA or protein. After stimulation with the proinflammatory cytokine IL-1, CCL28 mRNA and protein were significantly increased in the epithelium of colon but not small intestinal xenografts, although both upregulated the expression of another prototypic chemokine, CXCL8, in response to the identical stimulus. In studies of CCL28 regulation using human colon epithelial cell lines, proinflammatory stimuli, including IL-1, bacterial flagellin, and bacterial infection, significantly upregulated CCL28 mRNA expression and protein production. In addition, CCL28 mRNA expression and protein secretion by those cells were significantly increased by the short-chain fatty acid n-butyrate, and IL-1-or flagellin-stimulated upregulation of CCL28 by colon epithelial cells was synergistically increased by pretreatment of cells with n-butyrate. Consistent with its upregulated expression by proinflammatory stimuli, CCL28 mRNA expression was attenuated by pharmacological inhibitors of NF-B activation. These findings indicate that CCL28 functions as an "inflammatory" chemokine in human colon epithelium and suggest the notion that CCL28 may act to counterregulate colonic inflammation.
INTESTINAL EPITHELIAL CELLS produce mediators that can signal the chemoattraction of leukocyte populations important in mucosal innate and acquired immunity. For example, in response to stimulation with the proinflammatory mediators IL-1␣ or TNF-␣ or following infection with enteric pathogens, intestinal epithelial cells activate a group of proinflammatory genes, many of which are targets of the transcription factor NF-B (6, 13, 20 -22, 39) . The epithelial cell products of these genes can, in turn, activate the mucosal influx of neutrophils, monocytes, and dendritic cells (11, 20, 23, 35, 42) .
Chemokines are low-molecular-weight chemotactic cytokines that play a key role in leukocyte trafficking (4, 5, 32) and can be categorized into subfamilies based on the number and spacing of the NH 2 -terminal cysteines (2, 5) . For example, in the C-C chemokine subfamily, the first two cysteines are adjacent (3) . Chemokines are also classified based on functional criteria into those that are constitutively expressed (variably termed constitutive, homeostatic, or homing chemokines) and generally play a role in the homeostatic migration of leukocytes into and through different tissue compartments, e.g., CXCL13 (BCA-1), CXCL12 (SDF-1), CCL25 (TECK) (4, 25, 26, 32) , and inducible chemokines (also termed inflammatory chemokines) that are produced in response to microbial, inflammatory, and immune signals, e.g., CXCL8 (IL-8), CXCL1 (GRO␣), CCL2 (MCP-1), CXCL10 (IP-10) (3, 4, 32) .
CCL28 (also termed mucosal epithelial chemokine or MEC) is a member of the C-C chemokine subfamily and is constitutively expressed in different mucosal sites, including salivary and mammary glands, the trachea, as well as in the colon, and to a substantially lesser extent in the small intestine (34, 40) . CCL28 has been categorized as a constitutive chemokine important in homeostatic lymphocyte trafficking (25, 26) . The cognate receptor for CCL28 is CCR10 (40) .
CCL28 can chemoattract populations of CD4 and CD8 T cells that express CCR10 (40) . However, in the intestinal mucosa, few if any T cells are reported to express CCR10 (28) , suggesting that CCL28 may play another role in that site. Relative to other B cell populations, CCR10 appears to be expressed selectively by IgA plasmablasts and IgA-secreting cells (i.e., plasma cells) (28, 31) . Such studies indicate a possible role for CCL28 as a chemoattractant of IgA-committed B cells in the intestinal mucosa. As the most abundant isotype in human intestinal secretions, IgA is thought to increase intestinal mucosal defense through binding and preventing the mucosal entry of microbes, toxins, and other antigens and by neutralizing viruses (29) . IgA can also play a direct anti-inflammatory role by preventing bacterial LPS-induced NF-B activation in epithelial cells (14) , by neutralizing viruses within intestinal epithelial cells (7) , and possibly by excreting antigens from the subepithelial mucosal compartment across the epithelium into the intestinal lumen (24, 37) . To the extent that intestinal epithelial cell production of CCL28 influences mucosal IgA B cell migration and, similar to several other chemokines, mediates antimicrobial activity (8, 18) , CCL28 could contribute to the regulation of host mucosal defense and inflammation.
The proposed functional activities of CCL28 as a chemoattractant and antimicrobial protein led us to hypothesize that the production of CCL28 in human colon might not simply be constitutive, but might also manifest a more novel regulation compared with other intestinal epithelial chemokines. We re-port herein that CCL28 is significantly upregulated in inflamed colon epithelium, and its production is upregulated in human colon epithelial cells by proinflammatory stimuli alone or in combination with n-butryate, a product of bacterial metabolism. Moreover, CCL28 expression is regulated, in part, by the transcription factor NF-B.
MATERIALS AND METHODS
Reagents. Recombinant human (rh) IL-1␣, IL-6, IFN-␥, and TNF-␣ were from Peprotech (Rocky Hill, NJ). Mouse IgG 1 and sodium butyrate were from Sigma (St. Louis, MO). rhCCL28, biotinconjugated affinity-purified goat anti-human CCL28, and murine MAb to human CCL28 (clone 62705) were from R&D Systems (Minneapolis, MN). Cy3-conjugated goat anti-mouse IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA). and N-acetyl-leucinyl-leucinyl-norleucinal (ALLN) were from Calbiochem (La Jolla, CA). Purified H7 flagellin from Escherichia coli serotype O157:H7 strain 86 -24 was a gift of Y. Miyomoto (University of California San Diego).
Human colon epithelial cell lines. The human colon cell lines HCA-7, HT-29, HCT-8, and Caco-2, and the intestinal epithelial cell line I-407 were grown in DMEM supplemented with 10 or 15% (Caco-2) heat-inactivated FBS (9) . HT-29.19A cells were grown in McCoy's 5A medium with 10% FBS, and T84 cells were grown in 50% DMEM/50% Ham's F-12 medium with 5% newborn calf serum (23) . Media were supplemented with 2 mM L-glutamine. Cells were maintained in 95% air-5% CO 2 at 37°C.
Cell stimulation and infection. Cells in six-well tissue culture plates were stimulated with IL-1␣, IL-6, and TNF-␣ (each at 20 ng/ml) or IFN-␥ (40 ng/ml). For bacterial infections, cells were cultured in serum-free DMEM with 1 ϫ 10 8 colony-forming units of Salmonella serovar Dublin for 1 h, after which the bacteria were removed by washing and gentamicin (50 g/ml) was added to kill any remaining extracellular bacteria (11, 23) . To inhibit NF-B activation, cells were preincubated with 10 M BAY 11-7082 or 10 M of the calpain inhibitor ALLN for 45 min before the addition of IL-1␣.
RNA extraction and RT-PCR analysis. Total cellular RNA was extracted using an acid guanidinium-phenol-chloroform method (TRIzol reagent; GIBCO-BRL Life Technologies, Grand Island, NY). Reverse transcription and PCR amplification were performed as described before (16) . Primers for CCL28 were designed from sequences available from GenBank (AF220210); sense 5Ј-AGC CAT ACT TCC CAT TGC CTC C-3Ј and antisense 5Ј-GCC CTG TTA CTG TTC CTC TTG CC-3Ј and yielded a 276-bp product. Primers for IL-8 and ␤-actin were as described before (9, 23) . After a hot start, the amplification profile was 45 s of denaturation at 95°C and 2.5 min of annealing and extension at 62°C for 32 cycles for CCL28, 2 min of annealing and extension at 60°C for 30 cycles for IL-8, and 2 min of annealing and extension at 72°C for 28 cycles for ␤-actin. Negative control reactions contained no added RNA in the RT reaction and no added cDNA in the PCR amplification. Positive control reactions used RNA from peripheral blood mononuclear cells.
Real-time PCR. Real-time PCR was performed using an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA). Each reaction mixture contained 12.5 l 2ϫ SYBRgreen Master Mix (containing 200 M each of dATP, dGTP, and dCTP, 400 M dUTP, 2 mM MgCl2, 0.125 U uracil N-glycosylase, and 0.313 U Amplitaq Gold DNA polymerase; PE Biosystems), 6.25 pmol each of sense and antisense primer, and 1 l cDNA in a 25-l final volume. The CCL28 primers were as described above. Primer sequences for IL-8 were sense 5Ј-ATG ACT TCC AAG CTG GCC GTG GCT-3Ј and antisense 5Ј-TCT CAG CCC TCT TCA AAA ACT TCT C-3Ј. The ␤-actin primers were sense 5Ј-CAA AGA CCT GTA CGC CAA CAC-3Ј and antisense 5Ј-CAT ACT CCT GCT TGC TGA TCC-3Ј. Reaction mixtures were incubated at 50°C for 2 min followed by 95°C for 10 min to activate Amplitaq Gold DNA polymerase after which the amplification profile was 40 cycles of 15 s of denaturation at 95°C and 1 min of annealing at 60°C for CCL28 and ␤-actin. Amplification of the expected single products was confirmed on 1% agarose gels stained with ethidium bromide. Data analysis was done using Sequence Detection System software (PE Biosystems) provided by the manufacturer as described before (6, 16) . Fold changes in CCL28 mRNA expression were determined as 2 ⌬Ct , where (6, 16) .
Human intestinal xenografts. Human colon and small intestinal xenografts were generated as described before (12, 16, 20) . Briefly, human fetal colon or small intestine (Advanced Biosciences Resources, Alameda, CA) of 16-to 20-wk gestational age was transplanted subcutaneously onto the backs of C57BL/6 severe combined immunodeficient (SCID) mice and allowed to develop for at least 10 wk (12, 16, 20, 30, 38) . Mice with mature xenografts were injected intraperitoneally with 1 g human IL-1␣ in 200 l of PBS or PBS A, D, and G were immunostained for CCL28, and C, F, and I are adjacent sections stained with hematoxylin and eosin (H&E). CCL28 immunostaining was most marked in the inflamed colon (D, G) and restricted to epithelial cells. No immunostaining was seen in sections stained with the isotype-matched control antibody at same concentration (B, E, I). Original magnification, ϫ200. Similar results with no or minimal immunostaining for CCL28 were noted in normal colon from 3 additional healthy subjects. Ulcerative colitis is shown as a model of intestinal inflammation, and each of 5 patients examined with that disease had a marked increase in colon epithelial CCL28 similar to that shown, although such increases are not specific for ulcerative colitis and were also seen in other causes of colon inflammation as shown and in Crohn's colitis.
alone as a control. Colon or small intestinal xenografts were removed 5 h later, and adjacent segments were frozen in liquid nitrogen for RNA isolation, or for immunohistochemical analysis, they were embedded in optimal cutting temperature compound (TissueTek, Torrance, CA) and frozen in isopentane-dry ice or fixed in 10% neutral buffered formalin. All studies in this report using human and animal subjects were approved by the University of California, San Diego Human and Animal Subjects Committees.
Immunohistochemistry. Cultured epithelial cells were detached with 0.25% trypsin/0.1 mM EDTA, washed in serum-free DMEM, and resuspended in PBS. Aliquots were cytocentrifuged onto positively charged glass slides, which were air dried and fixed in acetone for 10 min at Ϫ20°C. For immunostaining, cells were rehydrated in PBS, blocked for 1 h with 1% BSA in PBS, and incubated overnight at 4°C with 10 g/ml mouse MAb to human CCL28 or control mouse IgG 1. Cy3-conjugated goat anti-mouse antibody was added as secondary antibody at a 1:200 dilution for 1 h. Nuclei were counterstained with Hoechst 33258 dye (100 ng/ml).
Cryostat sections (5 m) were prepared from human intestinal xenografts and from human colon biopsies obtained at colonoscopy from three normal individuals, five patients with ulcerative colitis, and two subjects with colon inflammation not due to ulcerative colitis (1 with Crohn's disease and 1 with inflammation in an area adjacent to a colon cancer). Sections were fixed in ice-cold acetone for 10 min, blocked in PBS-1% BSA with 10% goat serum for 1 h at room temperature, and immunostained for CCL28.
CCL28 enzyme-linked immunospot assay. 96-well polyvinylidene difluoride membrane plates (MAIP S4510, Millipore, Bedford, MA) were coated overnight at 4°C with 50 l of 5 g/ml mouse antihuman CCL28 MAb or isotype-matched control mouse mIgG 1 MAb in carbonate buffer, pH 9.3 (15 mM Na2CO3, 35 mM NaHCO3), washed with PBS, and then incubated for 1 h at 37°C with 50 M ␤-mercaptoethanol, 2 mg/ml NaHCO 3, 10% FCS, 2 mM L-glutamine, and 50 g/ml gentamicin in 100 l DMEM to block remaining free binding sites. After being washed in PBS, HCA-7 cells were added (1 ϫ 10 5 /well) and incubated for 24 h in 95% air-5% CO2 at 37°C, after which IL-1␣ (20 ng/ml) and n-butyrate (2 mM) or IL-1␣ plus n-butyrate were added and the plates were further incubated for an additional 24 h. Wells were washed with PBS plus 0.1% Tween 20 (PBST) and then incubated with 50 l of biotin-conjugated affinitypurified goat anti-human CCL28 (0.5 g/ml) in PBST containing 1% BSA overnight at 4°C. Reactions were developed using streptavidinalkaline phosphatase (Roche, Indianapolis, IN; 100 l of a 1:2,000 dilution in PBST containing 1% BSA) for 1 h at room temperature followed by 1 h incubation at room temperature with 100 l of a 1:50 dilution of Nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate (Roche) in 100 mM Tris buffer, pH 9.5, and 50 mM MgSO 4. Plates were air-dried overnight and photographed.
ELISA. HCA-7 cell supernatants were assayed for CCL28 using a solid-phase ELISA (Quantikine, R&D systems). The ELISA was sensitive to 10 pg/ml. 
RESULTS

Increased CCL28 expression in inflamed adult human colon.
CCL28 mRNA is constitutively expressed in the human colon and in several other mucosal sites leading to the concept that this chemokine controls the homeostatic trafficking of lymphocytes, which express its cognate receptor, to and within those sites (34, 40) . As a "homeostatic" chemokine, little to no attention has been focused on its possible regulated expression. During the course of characterizing chemokines produced by human colon epithelium, we made the novel finding that CCL28 was markedly increased in the epithelium of mucosal biopsies from inflamed compared with normal colon (Fig. 1) . This suggested that CCL28 production is not strictly constitutive in human colon epithelium, but rather, it is subject to regulation by proinflammatory stimuli.
Regulated CCL28 expression in human colon xenografts. To further define the regulated expression of CCL28 in intact human epithelium in vivo, we used a human intestinal xenograft model (12, 38) . In this model, human fetal colon or small intestine is transplanted subcutaneously onto the backs of SCID mice and allowed to mature for 10 wk. After maturation, these xenografts contain an epithelium that is strictly of human origin (38) . CCL28 mRNA was constitutively expressed at low levels in human colon xenografts, and little, if at all, by small intestinal xenografts ( Fig. 2A) . To determine whether CCL28 mRNA expression in the xenografts was upregulated by stimulation with a proinflammatory mediator, mice carrying either colon or small intestinal xenografts were injected with rhIL-1␣ or, as a control, PBS. IL-1␣ resulted in a marked upregulation of CCL28 mRNA in colon but not small intestinal xenografts as assessed by real-time PCR (Fig. 2B) . In contrast, human IL-8, which was assayed as a control inflammatory chemokine, was not constitutively expressed by the xenografts but was upregulated in both colon and small intestinal xenografts following IL-1␣ injection (Fig. 2, A and B) . Consistent with the low levels of constitutively expressed CCL28 mRNA in xenografts and upregulated expression after IL-1 injection, we found little, if any, CCL28 immunostaining in unstimulated xenografts but a marked increase in CCL28 immunostaining that was strictly localized to the colon epithelium in xenografts from IL-1␣-injected mice (Fig. 2C) .
CCL28 regulation in human intestinal epithelial cell lines. To study the putative role of specific agonists in the regulated expression of CCL28, we used established human colon epithelial cell lines. Several of these lines constitutively expressed CCL28 mRNA (Fig. 3A) . Because HCA-7 cells had the lowest background levels of constitutive CCL28 mRNA expression Fig. 4 . Regulated expression of CCL28 mRNA. A: HCA-7 cells were stimulated with IL-1␣ (20 ng/ml; ᮀ) or infected with S. dublin (s). Cells were harvested at the indicated times. CCL28 mRNA levels were assessed by real-time PCR and normalized to ␤-actin, which was nearly constant in all groups throughout the experiments. Data are expressed as the fold change in mRNA levels in stimulated or infected cultures relative to control cultures incubated for the same duration. Values are means Ϯ SE of 3 repeated experiments. *P Ͻ 0.05 compared with control cultures. B: HCA-7 cells were left unstimulated (control) or stimulated with IL-1␣ (20 ng/ml) for 18 h or with 2 mM butyrate for 24 h or were preincubated with 2 mM butyrate for 6 h, after which IL-1␣ (20 ng/ml) was added and cultures were incubated for an additional 18 h. CCL28 mRNA expression assessed by real-time PCR is expressed as in A. Values are means Ϯ SD from a representative experiment. Similar data were obtained in 2 repeated experiments. *P Ͻ 0.05 compared with control; **P Ͻ 0.05 compared with butyrate or IL-1␣. C: HCA-7 cells were left unstimulated (control), stimulated with IL-1␣ (20 ng/ml) or bacterial flagellin (100 ng/ml) for 18 h, or preincubated with 2 mM butyrate for 6 h, after which bacterial flagellin (100 ng/ml) was added and cultures were incubated for an additional 18 h. CCL28 mRNA expression was assessed as in A. Values are means Ϯ SD from a representative experiment. and thereby most closely resembled the low levels of CCL28 mRNA in the epithelium of human colon xenografts, HCA-7 colon epithelial cells were used for further studies of CCL28 regulation in vitro. As shown by qualitative RT-PCR in Fig.  3B , IL-1␣ (20 ng/ml) significantly increased CCL28 mRNA expression in those cells and, to a lesser extent, in two other cell lines tested (Caco-2, HT-29; not shown). In contrast, CCL28 mRNA expression was not significantly increased by TNF-␣ (20 ng/ml), IFN-␥ (40 ng/ml; Fig. 2B ), or IL-6 (20 ng/ml) stimulation. This was also the case when cells were stimulated for 6, 12, or 24 h with TNF-␣, IFN-␥, or IL-6 at titrated concentrations ranging from 1 to 100 ng/ml, and CCL28 mRNA levels were as assessed by real-time PCR, although those cytokines markedly upregulated the expression of other chemokines assayed as positive controls (e.g., CXCL8, CCL22, CCL10). By real-time RT-PCR, CCL28 mRNA levels increased by ϳ10-fold by 18 h after IL-1␣ stimulation (Fig.  4A ), but no further increase was seen over the same time course when cells were stimulated with IL-1␣ in combination with IFN-␥ (40 ng/ml) or TNF-␣ (20 ng/ml), and no significant increase in CCL28 mRNA levels above background were noted when cells were stimulated with IFN-␥ (40 ng/ml) plus TNF-␣ (20 ng/ml) in combination. In further studies, HCA-7 cells were infected with the enteroinvasive bacterial pathogen S. dublin, which is another potent proinflammatory stimulus for intestinal epithelial cells (11, 13, 23) . S. dublin infection increased CCL28 mRNA expression over a time course similar to that of IL-1, with maximal CCL28 mRNA levels being approximately twofold higher than those induced by IL-1 stimulation (Fig. 4A) .
Butyrate is a short-chain fatty acid that is generated in the colon by bacterial digestion of complex carbohydrates. It is known to regulate the expression of several epithelial cell genes and products that are important for host innate and acquired immune defense (17, 19, 36) and to increase the differentiation of cultured human colon epithelial cell lines, including HCA-7, Caco-2, and HT-29 (16) . Because initial reports noted that CCL28 mRNA was preferentially expressed in the colon, relative to the small intestine (34, 40) , and we found little, if any, constitutive CCL28 expression in colon xenografts, which lack a microbial flora (16), we hypothesized that exposure to bacterial products such as butyrate may have a role in regulating epithelial CCL28 expression. HCA-7 cells were incubated with butyrate, with or without IL-1␣. As shown in Fig. 3B , CCL28 expression was significantly increased when HCA-7 cells were incubated with butyrate. Moreover, pretreatment of HCA-7 cells with butyrate before IL-1 stimulation resulted in an ϳ100-fold synergistic increase in IL-1␣-stimulated CCL28 mRNA levels (Fig. 4B) .
IL-1 and bacterial flagellin share a common intracellular signaling pathway that is activated by signaling through the IL-1 receptor or human toll-like receptor 5 (1). Because CCL28 mRNA levels were markedly upregulated by stimulation with IL-1␣, but not by stimulation with TNF-␣, although both of these proinflammatory cytokines are potent activators of the transcription factor NF-B, we asked whether activation of human colon epithelial cells by bacterial flagellin, like IL-1␣ also activates CCL28. Bacterial flagellin used at optimal concentrations (100 ng/ml) upregulated CCL28 mRNA levels, and, similar to IL-1␣ stimulation, CCL28 mRNA levels were synergistically increased in flagellin-stimulated cells pretreated with butyrate (Fig. 4C) .
Consistent with the mRNA results, CCL28 protein was markedly increased in HCA-7 cells stimulated with IL-1␣ (Fig.  5A) . Furthermore, another potent proinflammatory stimulus, Salmonella infection, significantly increased CCL28 secretion CCL28 secretion in unstimulated cultures was 17 pg/ml at 6 h and 25 pg/ml at 24 h (not shown). B and C: HCA-7 cells were left unstimulated (control) or were stimulated with IL-1␣ (20 ng/ml) for 18 h or 2 mM butyrate for 24 h or were preincubated with 2 mM butyrate for 6 h, after which IL-1␣ (20 ng/ml) was added and cultures were incubated for an additional 18 h. CCL28 levels in supernatants were assayed by ELISA (B), and production of CCL28 by individual cells was determined by enzyme-linked immunospot assay (C). *P Ͻ 0.05 compared with control; **P Ͻ 0.05 compared with butyrate or IL-1␣. (Fig. 5A ). This increase was further enhanced by butyrate treatment of cells subsequently stimulated with IL-1␣ (Fig.  5B) . As shown by enzyme-linked immunospot assay (Fig. 5C ), agonist stimulation resulted in both greater numbers of cells producing CCL28 as well as more CCL28 production per cell, although there was marked cell-to-cell heterogeneity.
Finally, we hypothesized that CCL28 expression might, in part, be regulated by the transcription factor NF-B in light of its upregulated expression in response to IL-1␣ stimulation and Salmonella infection, both of which can activate NF-B through a similar intracellular signal-transduction pathway (13) . As shown in Fig. 6 , IL-1␣-stimulated CCL28 expression was significantly abrogated by two different pharmacological inhibitors of NF-B activation, BAY 11-7082 and ALLN, suggesting that NF-B has a role in regulating CCL28 expression.
DISCUSSION
CCL28 has been regarded as a constitutively expressed homeostatic chemokine involved in the migration of CCR10-expressing lymphocyte populations to mucosal sites. We demonstrate here that CCL28 production by colon epithelial cells is, in fact, upregulated by proinflammatory stimuli including microbial pathogens, microbial products, and proinflammatory cytokines. However, CCL28 differs from that of several other chemokines produced by the intestinal epithelium with respect to its regulated expression and its regional distribution in the intestinal tract. Although CXCL1, CXCL8, CCL2, and CCL20 are produced by intestinal epithelial cells, are upregulated by proinflammatory stimuli, and function as NF-B target genes (13, 20) , in contrast to CCL28, they are rapidly upregulated in colon epithelial cells within a few hours by either TNF-␣ or IL-1 (6, 20, 23, 42) . Several other chemokines produced by colon epithelial cells (e.g., CXCL9, CXCL10, CXCL11, CCL22) are upregulated by IFN-␥ alone or in synergy with TNF-␣ or IL-1 (6, 10), but this was not the case for CCL28. The upregulated expression of CCL28 in colon epithelium, but not in small intestinal epithelium, also differs from that of other inducible chemokines, which, in contrast, are abundantly produced by both colon and small intestinal epithelium (6, 20) . The selective production of CCL28 by colon relative to small intestinal epithelium also differs from that of CCL25, a chemokine that governs the homeostatic trafficking of CCR9-expressing lymphocytes, and is produced by small intestinal but not colonic epithelium (27, 41) . These findings, taken together, indicate that the regulation and distribution of CCL28 differ in several respects from those of previously described intestinal epithelial cell chemokines.
The short-chain fatty acid butyrate induced CCL28 production by cultured colon epithelial cells and synergistically increased colon epithelial cell CCL28 production in response to IL-1 or flagellin stimulation. The cathelicidin hCAP18/LL37 is an antimicrobial protein that also manifests chemoattractant activity. hCAP18/LL37, similar to CCL28, is preferentially produced by colonic compared with small intestinal epithelium, and we found its expression is also upregulated by butyrate (16) . Unlike CCL28, however, hCAP/LL37 was abundantly expressed by the epithelium of human colon xenografts in the absence of IL-1 stimulation (16) . Whereas butyrate increased IL-1-stimulated production of the neutrophil chemoattractant CXCL8 by a human colon epithelial cell line and MIP-2 secretion by a rat small intestinal epithelial cell line (15, 33) , in contrast to CCL28, butyrate stimulation by itself did not substantially upregulate the production of those chemokines. Taken together, these data suggest that butyrate, or other products generated by intestinal microbes, may have a role in regulating the constitutive expression of CCL28 by colonic epithelium in vivo. We note, however, that higher concentrations of butyrate than those we used to stimulate HCA7 cells are present in the colon, yet only low levels of CCL28 were expressed by colon epithelium in vivo in the absence of inflammation. Because butyrate has multiple effects on cellular functions, the marked effects of butyrate on CCL28 expression, as revealed in the cell line studies, may, in part, be masked by its other effects in vivo. Alternatively, results obtained with butyrate stimulation of colon epithelial cell lines may not be paralleled in normal colon epithelium in vivo.
Prior studies (18, 26, 28, 31, 34, 40) considered CCL28 to be a constitutively expressed mucosal chemokine and focused on its possible role in the homeostatic trafficking of CCR10-expressing T cells and/or populations of CCR10-expressing IgA B cells and its antimicrobial activity. Those studies did not consider that its expression in sites such as the colon may be regulated. As shown in vivo and in vitro, CCL28 production can be upregulated by specific proinflammatory signals, bacterial infection, and products of bacterial metabolism. To the extent that the targets of CCL28 predictably mediate antiinflammatory functions, our data suggest that CCL28 could have an important role in counterregulating mucosal inflammation in the colon.
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